A Phase I, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Fostamatinib Disodium in Healthy Japanese and White Subjects After Single and Multiple Ascending Doses.

Trial Profile

A Phase I, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Fostamatinib Disodium in Healthy Japanese and White Subjects After Single and Multiple Ascending Doses.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2015

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Rheumatoid arthritis; Solid tumours; T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Oct 2015 Results published in the European Journal of Clinical Pharmacology
    • 30 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Apr 2011 Planned end date changed from 1 Nov 2010 to 1 May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top